

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

INSIDE INFORMATION
ENTERING INTO LICENSE AGREEMENT WITH SEAGEN INC.
FOR HBM9033

This announcement is made by HBM Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that Nona Biosciences (Suzhou) Co., Ltd (“**Nona Biosciences**”), a subsidiary wholly-owned by the Company, and Seagen Inc. (“**Seagen**”) have entered into a license agreement (the “**Agreement**”) for the global clinical development and commercialization of HBM9033, being the mesothelin (“**MSLN**”) antibody-drug-conjugate (“**ADC**”), a worldwide potentially best-in-class product developed by the Nona Biosciences.

Pursuant to the Agreement, Nona Biosciences shall receive

- the aggregate amount of US\$53 million upfront and near-term payments,
- potential milestone payments based on certain pending development and commercial achievements of up to approximately US\$1.05 billion in aggregate; and
- tiered royalties on net sales up to high teens.

The Agreement marks a significant milestone in the business development of the Company’s Harbour Mice® Platform and its ADC Ecosphere, validating the potential of the Company’s technology platforms and innovation capabilities. The Company will also leverage on this opportunity to further strengthen its global cooperation network through its innovative collaboration model and maximize the scientific and commercial value of the Company’s technology platforms. Based on the above, the Board believes that entering into the Agreement is in the best interests of the Company and its shareholders as a whole.

The Agreement is of a revenue nature in the ordinary and usual course of business of the Group and does not constitute notifiable transaction under Chapter 14 of the Listing Rules.

ABOUT HBM9033

HBM9033 is an ADC drug that specifically targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in HBM9033 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to shedding MSLN (sMSLN) while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb ensures superior potency and safety in various preclinical tumor models with differing MSLN expression levels, positioning HBM9033 as a potential globally best-in-class therapeutic option.

ABOUT SEAGEN INC.

Seagen is a global biotechnology company that discovers, develops, manufactures, and commercializes targeted cancer therapeutics with ADCs. Pfizer has obtained necessary regulatory approvals and concluded the acquisition of Seagen on 14 December 2023.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that any products under the Agreement will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Forward-Looking Statements

This announcement may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 15 December 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.